Drug name - Venclexta

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546399 ABBVIE INC Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
Jun, 2031

(8 years from now)

US10730873 ABBVIE INC Salts and crystalline forms of an apoptosis-inducing agent
Nov, 2031

(9 years from now)

US8722657 ABBVIE INC Salts and crystalline forms of an apoptosis-inducing agent
Jan, 2032

(9 years from now)

CN103328474A ABBVIE INC Salt And Crystalline Cell Apoptosis Inducing Agent
Apr, 2018

(4 years ago)

CN104906100A ABBVIE INC Cell Procedure Death Inducing Medicine Preparation For Treating Cancer And Immune And Autoimmune Disease
Sep, 2019

(3 years ago)

CN109897038A ABBVIE INC For Programmed Cell Death-Inducing Agent For The Treatment Of Cancer And Immune And Autoimmune Diseases
May, 2030

(7 years from now)

CN102448959B ABBVIE INC Cell Procedure Death Inducing Medicine Preparation For Treating Cancer And Immune And Autoimmune Disease
May, 2030

(7 years from now)

CN102448959A ABBVIE INC Apoptosis-Inducing Agents For Treatment Of Cancer And Immune And Autoimmune Diseases
May, 2030

(7 years from now)

CN104876927B ABBVIE INC A Programmed Cell Death Inducing Agent For The Treatment Of Cancer And Immune And Autoimmune Diseases
May, 2030

(7 years from now)

CN104876927A ABBVIE INC For The Treatment Of Cancer And Immune And Autoimmune Diseases Of Programmed Cell Death Inducing Agent
May, 2030

(7 years from now)

CN109897038B ABBVIE INC Cell Programmed Death-Inducing Agent For The Treatment Of Cancer And Immune And Autoimmune Diseases
May, 2030

(7 years from now)

CN103153993B ABBVIE INC Cell Procedure Disease Death Inducing Agent For Treating Cancer And Immune And Autoimmune
Nov, 2030

(8 years from now)

CN103153993A ABBVIE INC Cell Procedure Disease Death Inducing Agent For Treating Cancer And Immune And Autoimmune
Nov, 2030

(8 years from now)

EP2435432B1 ABBVIE INC Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases
May, 2030

(7 years from now)

EP2435432A2 ABBVIE INC Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases
May, 2030

(7 years from now)

EP2576546A1 ABBVIE INC Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases
Nov, 2030

(8 years from now)

EP2576546B1 ABBVIE INC Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases
Nov, 2030

(8 years from now)

EP2643322A1 ABBVIE INC Salts And Crystalline Forms Of An Apoptosis-Inducing Agent
Nov, 2031

(9 years from now)

EP2643322B1 ABBVIE INC Salts And Crystalline Forms Of An Apoptosis-Inducing Agent
Nov, 2031

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174982 ABBVIE INC Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases May, 2030

(7 years from now)

US10993942 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor Sep, 2033

(10 years from now)

US9539251 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor Sep, 2033

(10 years from now)

US11110087 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor Sep, 2033

(10 years from now)

Drugs and Companies using VENETOCLAX ingredient

Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll); treatment in combination with azacitidine or decitabine or low-dose cytarabine of newly-diagnosed acute myeloid leukemia (aml) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy; treatment of patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up that includes a dose of 50 mg per day for 1 week followed by 100 mg per day for 1 week; Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic leukemia (sll) in combination with a ga101 antibody such as obinutuzumab for one or more dosing periods, wherein the cll or sll is a cd20-expressing cancer; Treatment of acute myeloid leukemia (aml) by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine in adults 75 years or older or having certain comorbidities according to a dose ramp-up including a 100 mg per day dose; treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up including a 100 mg per day dose

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.